Daniel Roque, MD
Neurology · Chapel Hill, NCNPI 1295908499
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,777 of the $2,694 with a category attached, or 66.0%. Insightec,inc accounts for 94.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $2,058 and has fallen 89.5% since, to $216 in 2025.
Across 17 payments — averaging $158.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insightec,inc$3K
- Boston Scientific$91
- Chiesi USA, Inc.$49
- Abbott$14
Across 37 payments — averaging $6167.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$204K
- Sage Therapeutics, LLC$24K
What the payments were for
- Travel & lodging$1,77766%
- Food & beverage$91734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insightec,inc | 14 | $2,541 |
| Boston Scientific | 1 | $91 |
| Chiesi USA, Inc. | 1 | $49 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Exablate$2,067
How this compares
$2,694 in reported general payments places this provider in the 65th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 12 | $680,906 |
| IngrezzaValbenazine Tosylate | 24 | $183,851 |
| NuplazidPimavanserin Tartrate | 13 | $61,558 |
| AustedoDeutetrabenazine | 11 | $52,829 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 130 | $6,532 |
| AmantadineAmantadine Hcl | 34 | $3,730 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 22 | $1,252 |
| Primidone | 72 | $1,122 |
| Pyridostigmine Bromide | 12 | $760 |
| RivastigmineRivastigmine Tartrate | 17 | $685 |
| Baclofen | 29 | $527 |
| Ropinirole Hcl | 15 | $445 |
| Clonazepam | 33 | $261 |
| Topiramate | 14 | $202 |
| Gabapentin | 20 | $177 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chapel Hill
- James HowardChapel Hill$294K
- O'Neill D'cruzChapel Hill$57K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
- Kevin KahnDurham$587K
- Sanjay IyerCharlotte$581K
- Mark SkeenDurham$562K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.